Allena Pharmaceuticals

Kidney and metabolic disorders


HBM contact: Dr Ulrich Geilinger

Company status: public

Allena Pharmaceuticals, USA, is late-stage clinical biopharma company developing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of patients with hyperoxaluria, the main cause of kidney stones.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171